Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

News About Reata Pharmaceuticals

January 19, 2021 0

Reata Pharmaceuticals The Positive News Prohost Biotech's interest in Reata Pharmaceuticals (RETA) started when we recognized …

bluebird bio: The Appealing Decision to Separate its Severe Genetic Disease and Oncology Businesses into Independent Publicly-Traded Firms

January 14, 2021 0

bluebird bio Decision to Separate its Businesses bluebird bio (BLUE) will retain focus on its severe genetic …

La Jolla Pharmaceutical Company Announced an Exclusive Licensing Agreement for GIAPREZA and XERAVA in Europe

January 12, 2021 0

La Jolla Pharmaceutical Company Announced an Exclusive Licensing Agreement for GIAPREZA and XERAVA La Jolla Pharmaceutical …

Underlining Exelixis Bright Future

January 11, 2021 0

Exelixis Bright Future Exelixis Fourth Quarter and Full Year 2020 Financial Results Exelixis (EXEL) announced …

For Those Still Asking Why the CRiSPR Gene Editing Stocks are Soaring

January 7, 2021 0

Intellia Therapeutics and CRISPR/Cas9 Technology Intellia Therapeutics (NTLA) is a genome editing company, focused on the …

Rhythm Pharmaceuticals: Successful Results from Phase 3 Trial with Setmelanotide for Obesity Caused by Genetic BBS

December 29, 2020 0

Rhythm Pharmaceuticals Announces Successful Phase 3 Trial Results for Obesity In November 2020, when the U.S. …

Inovio: Exciting News Published in The Lancet

December 24, 2020 0

Inovio Phase 1 Data of INO-4800 for COVID-19 Peer-reviewed Phase 1 data shows Inovio COVID-19 DNA …

Regenxbio: Advancing its Gene Therapy Pipeline and its Rare Neurodegenerative Disease Platform with Non-Dilutive Capital

December 23, 2020 0

Regenxbio Regenxbio (RGNX) announced that it is selling a portion of its royalty rights from the …

Compugen: More Highlighted News

December 23, 2020 0

Compugen Exclusive License Agreement with AstraZeneca In April 2018 Compugen (CGEN) and AstraZeneca (AZN) entered into …

Gilead Sciences has Good News for Relapsed or Refractory Mantle Cell Lymphoma and More

December 16, 2020 0

Gilead Sciences Company, Kite Pharma, News Kite Pharma, a Gilead Company (GILD), announced that the European Commission …

Intellia Therapeutics: Reinforcing the Promise of Potentially Curing Diseases

December 15, 2020 0

Intellia Therapeutics in the News Intellia Therapeutics (NTLA) presented the first demonstration of physiological protein levels …

Acquisitions that Make Sense

December 14, 2020 0

Acquisitions AstraZeneca Acquires Alexion Pharmaceuticals AstraZeneca (AZN) and Alexion Pharmaceuticals (ALXN) entered into a definitive agreement for …

Our Third Gene-Editing Pick is Joining its Two Sisters on the Road to Great Performances

December 10, 2020 0

CRISPR, Intellia and Editas, Our Gene-Editing Sisters, are Rallying The three CRISPR gene-editing firms that we …

The Biotechnology Industry

December 8, 2020 2

Prohost Letter #443 The Biotechnology Industry The Biotechnology Industry revolutionized the arts of life sciences with …

Why Reata Pharmaceuticals Stock is Down Today. See Also: Important News from Exelixis

December 2, 2020 0

Reata Pharmaceuticals: Why its Stock Price is Down Reata Pharmaceuticals (RETA) announced that it has priced …

Why Intellia Therapeutics’ and Moderna’s Stocks Moved South Yesterday

December 2, 2020 0

Intellia Therapeutics Intellia Therapeutics (NTLA) stock price headed south probably because some robots learned that the …

Regenxbio Announced the First Patient has been Dosed in the Phase I/II trial of RGX-111 for MPS I

December 1, 2020 0

Regenxbio Dosed First Patient with RGX-111 for MPS I Regenxbio (RGNX) has dosed the first patient …

The FDA Approved Rhythm Pharmaceuticals Product IMCIVREE™ for Genetic Obesity due to POMC, PCSK1 or LEPR Deficiency

December 1, 2020 0

Rhythm Pharmaceuticals FDA Approval of IMCIVREE™ for Genetic Obesity At the end of the trading week …

The Latest from Reata Pharmaceuticals. See Also: Prohost Picks that Reached the Moon in Today’s Trading

November 27, 2020 0

Reata Pharmaceuticals We picked Reata Pharmaceuticals (RETA) for investment after confirming that the products the Company …

The US FDA Approved Alnylam’s OXLUMO™ Injection to Lower Urinary Oxalate Levels in Pediatric and Adult Patients with PH1

November 24, 2020 0

Alnylam Announces FDA Approval of OXLUMO™ Injection for PH1 Alnylam (ALNY) announced that the US FDA …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

News About Reata Pharmaceuticals

bluebird bio: The Appealing Decision to Separate its Severe Genetic Disease and Oncology Businesses into Independent Publicly-Traded Firms

La Jolla Pharmaceutical Company Announced an Exclusive Licensing Agreement for GIAPREZA and XERAVA in Europe

Underlining Exelixis Bright Future

For Those Still Asking Why the CRiSPR Gene Editing Stocks are Soaring

Rhythm Pharmaceuticals: Successful Results from Phase 3 Trial with Setmelanotide for Obesity Caused by Genetic BBS

Inovio: Exciting News Published in The Lancet

Regenxbio: Advancing its Gene Therapy Pipeline and its Rare Neurodegenerative Disease Platform with Non-Dilutive Capital

Compugen: More Highlighted News

Gilead Sciences has Good News for Relapsed or Refractory Mantle Cell Lymphoma and More

Intellia Therapeutics: Reinforcing the Promise of Potentially Curing Diseases

Acquisitions that Make Sense

Our Third Gene-Editing Pick is Joining its Two Sisters on the Road to Great Performances

The Biotechnology Industry

Why Reata Pharmaceuticals Stock is Down Today. See Also: Important News from Exelixis

Why Intellia Therapeutics’ and Moderna’s Stocks Moved South Yesterday

Regenxbio Announced the First Patient has been Dosed in the Phase I/II trial of RGX-111 for MPS I

The FDA Approved Rhythm Pharmaceuticals Product IMCIVREE™ for Genetic Obesity due to POMC, PCSK1 or LEPR Deficiency

The Latest from Reata Pharmaceuticals. See Also: Prohost Picks that Reached the Moon in Today’s Trading

The US FDA Approved Alnylam’s OXLUMO™ Injection to Lower Urinary Oxalate Levels in Pediatric and Adult Patients with PH1